Ablynx Overview
Latest Deal Amount
$4.56B
Ablynx General Information
Description
Manufacturer of biopharmaceutical products created to offer proteins based therapeutics for treatment of inflammation, hematology, immuno-oncology, oncology and respiratory diseases. The company's biopharmaceutical products comprises of their patented product named, Nanobodies that is a therapeutic proteins based on single-chain antibody fragments that combine the benefits of drugs based on conventional antibodies and small chemical molecules, enabling patients avail various therapeutic and new drugs that can make a clear difference to society.
Ablynx Timeline
Want to dig into this profile?
We’ll help you find what you need
Learn more
Ablynx Valuation & Funding
| Deal Type |
Date |
Amount |
Raised to Date |
Post-Val |
Status |
Stage |
| 13. Merger/Acquisition |
19-Jun-2018 |
$4.56B |
00000 |
00.000 |
Completed |
Profitable |
| 12. Merger/Acquisition |
01-Dec-2017 |
00.000 |
|
00.000 |
Cancelled |
Profitable |
| 11. PIPE |
04-Oct-2017 |
|
00000 |
|
Completed |
Profitable |
| 10. Secondary Transaction - Open Market |
03-Nov-2016 |
|
00000 |
|
Completed |
Profitable |
| 9. PIPE |
01-Jun-2016 |
000.00 |
00000 |
|
Completed |
Profitable |
| 8. Secondary Transaction - Open Market |
18-Oct-2013 |
00.000 |
00000 |
|
Completed |
Generating Revenue |
| 7. 2PO |
16-Mar-2010 |
000.00 |
00000 |
|
Completed |
Generating Revenue |
| 6. IPO |
07-Nov-2007 |
00000 |
00000 |
|
Completed |
Generating Revenue |
| 5. Later Stage VC (Series C) |
23-Aug-2006 |
$51.2M |
$88.2M |
|
Completed |
Generating Revenue |
| 4. Early Stage VC (Series B) |
06-Apr-2004 |
$30.5M |
$37M |
|
Completed |
Generating Revenue |
Ablynx Competitors (32)
| Company Name |
Financing Status |
Location |
Employees |
Total Raised |
Last Financing Date/Type |
Last Financing
Amount |
| Lixte Biotechnology Holdings |
Corporation |
East Setauket, NY |
0 |
|
|
|
| 00000 |
Venture Capital-Backed |
Cambridge, United Kingdom |
000 |
00000 |
0000000000 0 |
00000 |
| 0000000 0000000000 |
Formerly VC-backed |
Newark, CA |
00 |
00000 |
00000000 |
00000 |
| 000000 |
Venture Capital-Backed |
Lebanon, NH |
000 |
00000 |
0000000000 0 |
00000 |
| 00000000 |
Venture Capital-Backed |
Tübingen, Germany |
000 |
00000 |
000000000000 |
00000 |
Ablynx Executive Team (17)
| Name |
Title |
Board Seat |
Contact Info |
| Wim Ottevaere |
Chief Financial Officer |
|
|
| Piet Houwen |
Chief Operating Officer |
|
|
| Robert Friesen Ph.D |
Chief Scientific Officer |
|
|
| Ludo Haazen MD |
Medical & Clinical Research Consultant |
|
|
| Russell Greig Ph.D |
Independent Director |
|
|
9 Former Executives
Ablynx Board Members (9)
To view Ablynx‘s full board member team, request access >>
| Name |
Representing |
Role |
Since |
| Catherine Moukheibir |
Self |
Independent Director & Board Member |
000 0000
|
| Geert Cauwenbergh Ph.D |
Self |
Board Member |
000 0000
|
| Remi Vermeiren |
Self |
Board Member |
000 0000
|
| Roger Perlmutter Ph.D |
Self |
Board Member |
000 0000
|
5 Former Board Members